Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 2/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Methoxyestradiol SCHEMBL13123068 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| 2-Methoxyestradiol SCHEMBL2610023 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| 2-Methoxyestradiol SCHEMBL8796 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| 2-Methoxyestradiol SCHEMBL26936622 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| 2-Methoxyestradiol SCHEMBL14252882 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| 2-Methoxyestradiol SCHEMBL23261536 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| 2-Methoxyestradiol SCHEMBL7052497 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| 2-Methoxyestradiol SCHEMBL29357742 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| SCHEMBL8489736 | 0.95 | CYP1A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 | |
| SCHEMBL4896510 | 0.95 | CYP1A1 (1.00) | CYP19A1CYP1A2CYP3A4HSD17B10CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2318 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3984537-B1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4257134-A2 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | Immunomedics, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3313443-B9 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | IMMUNOMEDICS INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3313443-B1 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | IMMUNOMEDICS INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230056203-A1 | METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS IN METASTASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-23 | — | — | US | claimed |
| US-20210154200-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | ONCOCEUTICS, INC. (US) | 2021-05-27 | — | — | US | claimed |
| US-10988539-B2 | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers | IMMUNOMEDICS, INC. (US) | 2021-04-27 | — | — | US | claimed |
| WO-2021067403-A1 | BIOMARKERS FOR ANTIBODY-DRUG CONJUGATE MONOTHERAPY OR COMBINATION THERAPY | IMMUNOMEDICS, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20210093730-A1 | BIOMARKERS FOR ANTIBODY-DRUG CONJUGATE MONOTHERAPY OR COMBINATION THERAPY | IMMUNOMEDICS, INC. | 2021-04-01 | — | — | US | claimed |
| US-10745479-B2 | TM4SF1 binding proteins and methods of using same | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-08-18 | — | — | US | claimed |
| WO-2000076487-A2 | USE OF PACLITAXEL AND STERIOD DERIVATIVES AS AROMATASE INHIBITORS FOR THE TREATMENT OF CANCER | STERIX LIMITED (GB) | 2000-12-21 | — | — | WO | claimed |
| WO-2000048606-A1 | COMPOSITIONS AND METHODS FOR USE IN TARGETING VASCULAR DESTRUCTION | OXIGENE, INC. (US) | 2000-08-24 | — | — | WO | claimed |
| JP-2000507923-A | — | — | 2000-06-27 | — | — | JP | claimed |
| EP-0833641-A4 | TREATMENT AND PREVENTION OF PROSTATIC DISEASE | MERCK & CO INC (US) | 2000-04-05 | — | — | EP | claimed |
| US-5962445-A | Treatment of asthma and airway diseases | AMRAD OPERATIONS PTY LTD. (AU) | 1999-10-05 | — | — | US | claimed |
| EP-0923376-A1 | TREATMENT OF ASTHMA AND AIRWAY DISEASES | Amrad Operations Pty.,Ltd. (AU) | 1999-06-23 | — | — | EP | claimed |
| WO-1999001142-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANGIOSTATIC STEROID COMBINED WITH A HYALURONAN | HYAL PHARMACEUTICAL CORPORATION (CA) | 1999-01-14 | — | — | WO | claimed |
| EP-0833641-A1 | TREATMENT AND PREVENTION OF PROSTATIC DISEASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997042958-A1 | TREATMENT OF ASTHMA AND AIRWAY DISEASES | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-11-20 | — | — | WO | claimed |
| WO-1996040150-A1 | TREATMENT AND PREVENTION OF PROSTATIC DISEASE | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | claimed |